The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

Korea GSK announced on the 29th that it will begin administering the world's first respiratory syncytial virus (RSV) vaccine, Arexvy. It will be available for vaccination at hospitals and clinics ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

Hospital tests eventually revealed that her 95-year-old mother Jane Tan (not her real name) had respiratory syncytial virus (RSV). “She couldn’t breathe at all,” recalls Ms Chua.

CNW/ -- (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...